Real-oWorld Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation

被引：0
|
作者：
Yan, Vincent K. C. [1 ]
Yu, Yang [1 ]
Wan, Eric Y. F. [2 ,3 ]
Wong, Ian Chi Kei [1 ]
Chan, Esther W. [1 ]
机构：
[1] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pharmacol & Pharm, Ctr Safe Medicat Practice & Res, Hong Kong, Peoples R China
[2] Univ Hong Kong, Li Ka Shing Fac Med, Dept Family Med & Primary Care, Hong Kong, Peoples R China
[3] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pharmacol & Pharm, Hong Kong, Peoples R China
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
496
引用
收藏
页码：202 / 202
页数：1
相关论文
共 50 条
  • [41] Comparative Effectiveness and Safety of Different Hydroxychloroquine Doses for Patients with Systemic Lupus Erythematosus: Nationwide Analysis Using Target Trial Emulation Framework
    Li, Brian Meng-Hsun
    Weng, Meng-Yu
    Lai, Edward Chia-Cheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 60 - 60
  • [42] Effectiveness and safety of direct oral anticoagulants vs VKA in patients on chronic dialysis: a target trial emulation using nationwide registry data
    Laville, Solene M.
    Couchoud, Cecile
    Choukroun, Gabriel
    Liabeuf, Sophie
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I143 - I144
  • [43] TARGET TRIAL EMULATION (TTE) FOR REAL WORLD DATA ANALYSES TO SUPPORT HTA DECISIONS
    Bennett, A.
    Kreif, N.
    Manca, A.
    VALUE IN HEALTH, 2022, 25 (12) : S359 - S360
  • [44] Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients
    Schiaroli, Elisabetta
    Gidari, Anna
    Brachelente, Giovanni
    Bicchieraro, Giulia
    Spaccapelo, Roberta
    Bastianelli, Sabrina
    Pierucci, Sara
    Busti, Chiara
    Pallotto, Carlo
    Malincarne, Lisa
    Camilloni, Barbara
    Falcinelli, Flavio
    De Socio, Giuseppe Vittorio
    Villa, Alfredo
    Mencacci, Antonella
    Francisci, Daniela
    JOURNAL OF CLINICAL VIROLOGY, 2023, 168
  • [45] REAL-WORLD EVIDENCE OF MULTI-GENE PANEL SEQUENCING EFFECTIVENESS AND COST-EFFECTIVENESS FOR ADVANCED CANCERS: A TUMOR-AGNOSTIC TARGET TRIAL EMULATION
    Krebs, E.
    Weymann, D.
    Regier, D.
    VALUE IN HEALTH, 2024, 27 (12) : S167 - S167
  • [46] Comparative Effectiveness of Second-Line Glucose-Lowering Medications-Emulation of a Target Trial Using Real-World Data
    Deng, Yihong
    Polley, Eric
    Wallach, Joshua D.
    Herrin, Jeph
    Ross, Joseph
    McCoy, Rozalina G.
    DIABETES, 2023, 72
  • [47] Safety of Triptans in Patients Who Have or Are at High Risk for Cardiovascular Disease: A Target Trial Emulation
    Wang, Zhen
    Vanderpluym, Juliana H.
    Singh, Rashmi B. Halker
    Alsibai, Reem A.
    Roellinger, Daniel L.
    Firwana, Mohammed
    Murad, Mohammad Hassan
    MAYO CLINIC PROCEEDINGS, 2024, 99 (11) : 1722 - 1731
  • [48] Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial
    Hobbs, F. D. Richard
    Montgomery, Hugh
    Padilla, Francisco
    Simon-Campos, Jesus Abraham
    Arbetter, Douglas
    Seegobin, Seth
    Kiazand, Alexandre
    Streicher, Katie
    Martinez-Alier, Nuria
    Cohen, Taylor S.
    Esser, Mark T.
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (03) : 521 - 533
  • [49] IMPROVING RHEUMATOID ARTHRITIS COMPARATIVE EFFECTIVENESS RESEARCH USING THE TARGET TRIAL EMULATION FRAMEWORK: A SYSTEMATIC REVIEW
    Zhao, S. S.
    Lyu, H.
    Solomon, D.
    Yoshida, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 854 - 855
  • [50] Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation
    Breskin, Alexander
    Wiener, Catherine
    Adimora, Adaora A.
    Brown Jr, Robert S.
    Landis, Charles
    Reddy, K. Rajender
    Verna, Elizabeth C.
    Crawford, Julie M.
    Mospan, Andrea
    Fried, Michael W.
    Brookhart, M. Alan
    EPIDEMIOLOGY, 2023, 34 (03) : 365 - 375
12345